VANCOUVER, BC and LANDERA RANCH, CA March 10, 2026 -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys") and Adiverna LLC ("Adiverna") announce today that they have entered into a Research Agreement ("Agreement") to develop mRNA-based Rabies, Leptospirosis, Feline Infectious Peritonitis (FIV and other mRNA-based vaccines for companion animal veterinary applications (dogs and cats).  The collaboration utilizes BioVaxys' DPX™ Immune Educating Platform ("DPX") formulations with novel proprietary mRNA sequences coding for protective antigens designed and developed by Adiverna.

Adiverna is pioneering a unique approach in veterinary healthcare by leveraging its proprietary artificial intelligence technology to design and optimize mRNA sequences for vaccines specifically tailored for companion animals. Currently, no mRNA vaccines are approved for these animals, making Adiverna's focus on this area groundbreaking. By utilizing machine learning algorithms and advanced bioinformatics, Adiverna's AI platform analyzes extensive datasets to identify and predict the most effective mRNA sequences that code for protective broadly cross-neutralizing antigens against diseases such as FIV, rabies, and leptospirosis. Additionally, Adiverna's mRNA platform offers significant dose-sparing potential, reducing the amount of vaccine required while still eliciting robust immune responses.

The BioVaxys DPX platform is a major innovation in vaccine development that offers a solution to limitations faced by vaccines using other antigen delivery methods, such as lipid nanoparticles. The DPX platform presents antigens, or multiple antigens, to the immune system using a novel non-systemic mechanism of action that does not release active ingredients at the site of the injection, but rather forces an active uptake of immune cells and delivery into the lymphatic nodes. The programming of immune cells happens in vivo and offers a more efficient approach that mimics the natural function of the immune system. This "no release" mechanism allows for an active uptake of antigens such as mRNA and other polynucleotides, peptides, proteins, and virus-like particles, into immune cells and lymph nodes for a sustained activation of the immune system in which the T cell flow is sustained over a longer duration than traditional vaccines.  

Traditional vaccines for companion animals are generally effective for either 1 year or 3 years, depending on the specific product used and local, state, or provincial regulations. While current rabies vaccines usually last one year, subsequent boosters can be labeled for three years of protection.  A DPX-formulated mRNA vaccines would offer significant advantages over traditional vaccines by delivering superior, longer-lasting immunity with fewer doses, together with high-level, rapid, and durable neutralizing antibody responses and faster, safer, and more scalable manufacturing.  A DPX mRNA vaccine would not use viral material and would have fewer impurities, reducing risks associated with injecting foreign, inactivated viruses, and would incorporate other DPX platform advantages including non-systemic depot delivery, micro-dosing, excellent shelf-life stability, and clinically demonstrated efficacy, safety and tolerability in both human and animal health use.

There are currently no approved mRNA vaccines for commercial use in companion animals.  However, the mRNA vaccine market is evolving, and there are emerging preclinical studies showing their efficacy in producing neutralizing protective immune response in target animals.  

Kenneth Kovan, President and Chief Operating Officer of BioVaxys says “Challenges faced by LNP-based vaccine formulations are it can spill out of the injection site leading to systemic inflammatory responses, with their systemic delivery leading to degradation by nucleases and removal by macrophage phagocytosis.  Due to their relatively short half-life, LNPs can also show instability under in vivo conditions, and with degradation affecting their storage, delivery, and overall efficiency.”  Kovan adds that “Data from proof-of-concept studies of DPX-mRNA formulations demonstrate that DPX provides enhanced in vitro and in vivo stability of packaged mRNA, attracts a therapeutically unique subset of Antigen Presenting Cells (APCs) to the injection site for targeted uptake of mRNA by the immune system, and that immunization with DPX containing mRNA induces specific immune responses towards encoded antigens.”

The global rabies veterinary vaccines market for inactivated and modified-live virus vector products is valued at US$785 million in 2024, and is projected to reach approximately US$1.1 billion by 2030, growing at a 5.8% CAGR. Annual sales for canine leptospirosis killed vaccine formulations are part of the broader dog vaccine market, which was valued at approximately $2.10 billion in 2025, however short durability, serotype specificity and adverse reactions make these vaccines difficult to apply. The FIV vaccine market is part of the broader feline vaccines sector, which is projected to reach USD 3.28 billion by 2034, growing from USD 1.77 billion in 2025.

Driven by mandatory pet vaccinations, increasing disease awareness, and rising pet ownership, the market is dominated by companion animal vaccination in North America, with the Asia /Pacific region experiencing rapid growth due to increasing vaccination campaigns in countries like India and China.1  

“We are very excited to be working with Adiverna to develop what could be the world’s first mRNA veterinary vaccine.  We believe the clinically proven advantages of the DPX platform formulated with Adiverna’s AI-designed mRNA sequences will provide for a superior product, adds Kovan.  “With demonstrated in vivo proof of concept of DPX mRNA formulations, this ‘proof of product’ will further our partnering discussions utilizing DPX mRNA formulations in human therapeutic applications.”

About BioVaxys Technology Corp.

BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it's HapTenix© tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization for food allergy, and other immunological diseases. Through a differentiated mechanism of action, the DPX™ platform delivers instruction to the immune system to generate a specific, robust, and persistent immune response. The Company's clinical stage pipeline includes maveropepimut-S (MVP-S), based on the DPX™ platform, in phase IIB clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. MVP-S delivers antigenic peptides from the survivin family, a set of well-recognized cancer antigens commonly overexpressed in advanced cancers, and also delivers an innate immune activator and a universal CD4 T cell helper peptide. MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation of a targeted and sustained, survivin-specific anti-tumor immune response. BioVaxys is also developing DPX™+SurMAGE, a dual-targeted immunotherapy combining antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously, DPX™-RSV for Respiratory Syncytial Virus, DPX+rPA for peanut allergy prophylaxis, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix© 'neoantigen' tumor cell construct platform for refractive late-stage ovarian cancer.

BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FSE: 5LB0) and in the U.S. on the OTC Markets (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.

About ADIVERNA LLC

Adiverna (www.adiverna.com) is an innovative biopharmaceutical company dedicated to advancing veterinary medicine through the development of cutting-edge mRNA-based vaccines and therapies. Registered in Ladera Ranch, CA, Adiverna focuses on enhancing the health and well-being of companion animals by utilizing its proprietary mRNA technology platform, which enables the design of precise and effective immunizations against various infectious diseases and conditions.

Leveraging a unique mechanism of action, Adiverna's mRNA vaccines provide the immune system with the genetic instructions to produce specific antigens, resulting in a targeted and robust immune response. This approach aims to overcome the limitations of traditional vaccines by offering faster development times and improved efficacy.

Adiverna's clinical pipeline includes several promising candidates, notably its lead mRNA vaccine designed to protect against common viral infections in pets. This vaccine aims to activate a strong immune response, providing long-lasting protection while minimizing the risk of adverse effects. Additionally, Adiverna is exploring mRNA formulations for combination vaccines that address multiple pathogens simultaneously, thereby simplifying vaccination protocols for pet owners and veterinarians.

The company is committed to demonstrating the safety and efficacy of its mRNA vaccines through rigorous clinical trials, ensuring they meet the highest standards of veterinary care. Adiverna's innovative solutions position it at the forefront of veterinary immunotherapy, with the potential to significantly improve the lives of companion animals.

Visist www.adiverna.com and connect with us on social media platforms like X and LinkedIn.

ON BEHALF OF THE BIOVAXYS BOARD

Signed "James Passin"
James Passin, Chief Executive Officer
Phone: +1 740 358 0555

ON BEHALF OF ADIVERNA

Signed “Kirill Kalnin, PhD”

Kirill V. Kalnin, PhD, Founder and Chief Technology Officer

Phone: +1 857 262 3580

Cautionary Statements on Forward-Looking Information

This news release includes certain "forward-looking information" and "forward-looking statements" (collectively "forward-looking statements") within the meaning of applicable securities legislation. All statements, other than statements of historical fact, included herein, without limitation, statements relating to the future operating or financial performance of the Company, are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or "should" occur or be achieved. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements.

Forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by BioVaxys, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies including, primarily but without limitation, the risk that BioVaxys' vaccines will not prove to be effective and/ or will not receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about whether its products will complete the long, complex and expensive clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval, uncertainty about whether its DPX platform can be developed to produce safe and effective products and, if so, whether its vaccine products will be commercially accepted and profitable, the expenses, delays and uncertainties and complications typically encountered by development stage biopharmaceutical businesses, financial and development obligations under license arrangements in order to protect its rights to its products and technologies, obtaining and protecting new intellectual property rights and avoiding infringement to third parties and their dependence on manufacturing by third parties.

Many factors, both known and unknown, could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements and the parties have made assumptions and estimates based on or related to many of these factors. BioVaxys does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by applicable securities laws.

Copyright (c) 2026 TheNewswire - All rights reserved.